Cephalon

Company

Investment-firm

Financing round

General

About Company
Teva Pharmaceuticals is a global pharmaceutical company that develops and sells affordable generic drugs.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.1987

Number of employees

Company Type

For Profit

IPO status

Private

Description

Teva Pharmaceuticals, headquartered in Israel, is the world's leading generic drug maker with a product portfolio of over 1,000 molecules. They have a strong presence in approximately 60 countries and focus on therapeutic areas such as CNS, respiratory oncology, pain, and women's health. Teva employs around 45,000 people worldwide and had net revenues of $20.3 billion in 2013.
Contacts

Contact Email

Phone number

Social url

Similar Companies
999
Vertex Pharmaceuticals

Vertex Pharmaceuticals

Vertex is a global biotech company creating transformative medicines for serious diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Pharmaceuticals, Health Care

Location

Boston, MA, USA

total rounds

7

total raised

$657.31M

count Of Investments

5
Ionis Pharmaceuticals

Ionis Pharmaceuticals

Ionis Pharmaceuticals is a leading company in the field of RNA-targeted therapeutics.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Pharmaceuticals, Health Care

Location

Carlsbad, CA, USA

total rounds

3

total raised

$1.25B

count Of Investments

4
Conatus Pharmaceuticals

Conatus Pharmaceuticals

Conatus Pharmaceuticals is a biotechnology company focused on developing and commercializing innovative medicines to treat chronic diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Pharmaceuticals

Location

San Diego, CA, USA

total rounds

6

total raised

$62.1M
Dyax

Dyax

Dyax Corp. is a biopharmaceutical company that develops and commercializes biotherapeutics for unmet medical needs.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Pharmaceuticals

Location

Cambridge, MA, USA
M&A Details
1

Acquired by

Teva Pharmaceutical Industries

announced date

02.05.2011

price

$6.8B

Financials

Investments
6
Date 
name 
Lead 
type 
Raised 
25.02.2011
Yes
$24.47M
Local Amount - JPY 2B
11.12.2009
No
$24.7M
Local Amount - JPY 2.2B
15.04.2009
No
$8.96M
Local Amount - JPY 888.48M
SymBio Pharmaceuticals

SymBio Pharmaceuticals

SymBio Pharmaceuticals creates therapeutic products for cancer, hematology, and autoimmune diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Tokyo, Japan

total rounds

13

total raised

$745.85M
SymBio Pharmaceuticals

SymBio Pharmaceuticals

SymBio Pharmaceuticals creates therapeutic products for cancer, hematology, and autoimmune diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Tokyo, Japan

total rounds

13

total raised

$745.85M
SymBio Pharmaceuticals

SymBio Pharmaceuticals

SymBio Pharmaceuticals creates therapeutic products for cancer, hematology, and autoimmune diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Tokyo, Japan

total rounds

13

total raised

$745.85M
Co-Investors
Acquisitions
6
ChemGenex Pharmaceuticals acquired by Cephalon

ChemGenex Pharmaceuticals acquired by Cephalon

acquirer

Cephalon
Cephalon

date

29.03.2011

type

Acquisition

price

$225M
ChemGenex Pharmaceuticals

ChemGenex Pharmaceuticals

ChemGenex Pharmaceuticals is an integrated biopharmaceutical development company focused on discovering and developing oncology drugs.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Pharmaceuticals, Biopharma

Location

Geelong VIC 3220, Australia

total rounds

1

total raised

$16.44M
Gemin X Pharmaceuticals acquired by Cephalon

Gemin X Pharmaceuticals acquired by Cephalon

acquirer

Cephalon
Cephalon

date

21.03.2011

type

Acquisition

price

$525M
Gemin X Pharmaceuticals

Gemin X Pharmaceuticals

Gemin X Pharmaceuticals develops targeted cancer therapeutics to improve patients' lives.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Dorval, QC, Canada

total rounds

6

total raised

$71.26M
Ception Therapeutics acquired by Cephalon

Ception Therapeutics acquired by Cephalon

acquirer

Cephalon
Cephalon

date

23.02.2010

type

Acquisition

price

$250M
Ception Therapeutics

Ception Therapeutics

Ception Therapeutics is a biopharmaceutical company developing novel products to address areas of unmet medical needs.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Pharmaceuticals, Health Care

Location

Malvern, PA 19355, USA

total rounds

2

total raised

$77.7M

People

Founders
1
Noubar Afeyan
Noubar Afeyan

Noubar Afeyan

Noubar Afeyan is Founder, Senior Managing Partner and Chief Executive Officer at Flagship Ventures, a leading early stage venture capital firm. Noubar also leads the firm's VentureLabs unit that invents and launches transformative startups. Noubar is a Senior Lecturer at MIT’s Sloan School of Management where he has taught courses on technology-entrepreneurship, innovation and leadership since 2000. Noubar lectures widely in the United States and internationally on diverse topics ranging from entrepreneurship, innovation and venture capital to biological engineering, drug discovery, medical technologies and renewable energy. During his 28-year career as inventor, entrepreneur, CEO and venture capitalist, Noubar has co-founded and helped build over 35 successful life science and technology startups. Noubar was Founder and Chief Executive Officer at PerSeptive Biosystems, a leader in the bio-instrumentation field that grew to over $100M in annual sales within six years from its first sales. After PerSeptive's acquisition by Perkin Elmer/Applera Corporation in 1998, Noubar was Senior Vice President and Chief Business Officer of Applera, where he initiated and oversaw the creation of Celera Genomics. Currently Noubar serves on a number of public and private company boards including CiBO Technologies, Epiva BioSciences, Evelo BioSciences, Joule Unlimited, Kaleido BioSciences, Moderna Therapeutics, Pronutria Biosciences and Seres Therapeutics. Previously, Noubar was a Member of the founding team, Director and Investor in several highly successful ventures including Chemgenics Pharmaceuticals (acquired by Millennium Pharmaceuticals), Color Kinetics (acquired by Philips), Adnexus Therapeutics (acquired by Bristol-Myers Squibb) and Affinnova (acquired by AC Nielsen). Noubar received a Technology Pioneer 2012 award from the World Economic Forum in recognition of the breakthrough solar fuel technology being developed at Joule Unlimited. Noubar has served as Chairman of the Global Agenda Council on Chemicals, Advanced Materials and Biotechnology of the World Economic Forum as well as being a member of the Meta-Council on Emerging Technologies. Noubar is a Member of the Board of Overseers of the Boston Symphony Orchestra. In addition, he serves on the board of AmeriaBank and of UWC Dilijan International School, both of Armenia. Previously, Noubar was a Co-Founder and Member of the Board of Directors at National Competitiveness Foundation of Armenia, a private-public partnership dedicated to promoting economic development in the former Soviet Republic of Armenia. In 2008 Noubar received the Ellis Island Medal of Honor, an award granted to outstanding Americans who have distinguished themselves as United States citizens and who have enabled their ancestry groups to maintain their identities while becoming integral parts of American life. Noubar has authored numerous scientific publications and patents since earning his Ph.D. in Biochemical Engineering from MIT in 1987. Cygnal is a best-in-class team of biomedical experts and leaders collaborating to revolutionize how the world treats diseases.

current job

Omega Therapeutics
Omega Therapeutics

organization founded

28

Noubar Afeyan

Employee Profiles
11
Piyush Patel

Piyush Patel

Director

Patrick Hutchison

Vice President-Group Controller

H. Jeffrey Wilkins

H. Jeffrey Wilkins

Vice President of Worldwide Clinical Development: Oncology and Immunology

Chris Rivera

Chris Rivera

Sales, Marketing, Commercial Operations and Management

Charles A. Reinhart III

Vice President of Finance

Robert McNeil

Robert McNeil

Investor (GeminX)

Frank Baldino, Jr.

Chairman & CEO

Activity

Recent News
1